



## PARKINSON'S DISEASE NEWS

<http://www.viartis.net/parkinsons.disease/news.htm>

26th July 2012 - News release

### SINGLE DRUG FOR PARKINSON'S, ALZHEIMER'S AND MULTIPLE SCLEROSIS

A new class of drug is being developed at Northwestern University as a single therapy for Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and traumatic brain injury by reducing inflammation in the brain. Northwestern University has been issued patents to cover this new drug class and has licensed the commercial development to a biotech company that has recently completed the first human Phase 1 clinical trial for the drug. The drugs in this class, represented by MW151 and MW189, target a particular type of brain inflammation, which they claim is a common denominator in these neurological disorders, as well as in traumatic brain injury and stroke. They claim that brain inflammation plays a major role in the progressive damage characteristic of these chronic diseases and brain injuries. For more information, go to the News release :

<http://www.northwestern.edu/newscenter/stories/2012/07/brain-inflammation-drug.html>

Despite their claims, there is no evidence that inflammation is a primary cause of Parkinson's Disease. Parkinson's Disease has been shown to be due to the insufficient formation of dopamine, which is completely unaccounted for by this method. Their recent study solely concerned Alzheimer's Disease in mice who did not even have Alzheimer's Disease, and was not shown to rid or reduce Alzheimer's Disease. They have not obtained any evidence at all concerning efficacy in Parkinson's Disease.

<http://www.viartis.net/parkinsons.disease/news/120726.pdf>

[mail@viartis.net](mailto:mail@viartis.net)

©2012 Viartis